Drug intelligence / Profile preview

OSP8201

Development stage: Preclinical
Lead developer: Oncocross
Modality: Small Molecules
Administration: Oral

Overview

OSP8201 is a preclinical drug candidate being developed by Oncocross in collaboration with a partner for the treatment of Dravet Syndrome. The candidate was identified using Oncocross's RAPTOR AI™ platform, which utilizes AI-driven transcriptomic analysis to identify new therapeutic indications for existing drugs or drug candidates (drug repositioning). OSP8201 is currently in the preclinical stage, specifically identified as an in silico asset aimed at addressing the severe seizures and developmental challenges associated with Dravet Syndrome, a rare genetic epileptic encephalopathy.

Beyond the preview

Go deeper on OSP8201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OSP8201.

Explore the full profile